ArticleFEBS letters2025
The solution supramolecular structure of α2 → 8 polysialic acid suggests a structural cause for its low immunogenicity.
Article in FEBS letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
α2 → 8 polysialic acid (polySia), the capsular polysaccharide on Neisseria meningitidis serogroup B and Escherichia coli K1, elicits poor immunogenic properties. A solution structure might clarify the cause. From X-ray and neutron small-angle scattering, we find that the solution supramolecular structure of polySia exhibits parallel-chain binding. Also, striking structural changes occur upon the addition of calcium to these solutions but still with the parallel motif. The major histocompatibility complex requires entities in the molecular weight range of 600-3000 Da, but the solution structures determined here argue that in endosomes polySia oligomers of the correct size to be immunologically effective are instead bound up as parallel chains. This is expected to reduce the possible concentrations of the effective oligomers and so reduce the immunogenic capability of α2 → 8 polysialic acid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.